Oarsman Capital Inc. grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.1% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 34,949 shares of the biopharmaceutical company’s stock after buying an additional 378 shares during the period. Gilead Sciences accounts for 1.1% of Oarsman Capital Inc.’s investment portfolio, making the stock its 27th largest holding. Oarsman Capital Inc.’s holdings in Gilead Sciences were worth $2,474,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of GILD. Harel Insurance Investments & Financial Services Ltd. boosted its stake in Gilead Sciences by 583.3% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 1,400 shares during the period. Penserra Capital Management LLC boosted its stake in Gilead Sciences by 9.5% during the 1st quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 144 shares during the period. American Beacon Advisors Inc. acquired a new stake in Gilead Sciences during the 1st quarter worth $143,000. Sterling Investment Advisors Ltd. acquired a new stake in Gilead Sciences during the 2nd quarter worth $184,000. Finally, Washington Trust Bank boosted its stake in Gilead Sciences by 24.8% during the 2nd quarter. Washington Trust Bank now owns 2,767 shares of the biopharmaceutical company’s stock worth $196,000 after purchasing an additional 550 shares during the period. Institutional investors and hedge funds own 74.62% of the company’s stock.

GILD has been the subject of a number of recent research reports. BMO Capital Markets reiterated a “hold” rating and set a $82.00 price target on shares of Gilead Sciences in a research note on Friday, October 20th. J P Morgan Chase & Co set a $85.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Wednesday, October 25th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Monday, August 28th. Vetr upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $89.27 price target for the company in a research note on Wednesday, September 6th. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $83.00 price target (up previously from $77.00) on shares of Gilead Sciences in a research note on Friday, October 6th. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $84.87.

ILLEGAL ACTIVITY NOTICE: This report was posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://theolympiareport.com/2017/11/19/gilead-sciences-inc-gild-shares-bought-by-oarsman-capital-inc.html.

Gilead Sciences, Inc. (GILD) opened at $72.44 on Friday. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10. Gilead Sciences, Inc. has a twelve month low of $63.76 and a twelve month high of $86.27. The firm has a market cap of $94,626.13, a PE ratio of 7.56, a price-to-earnings-growth ratio of -1.21 and a beta of 1.13.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The firm had revenue of $6.51 billion during the quarter, compared to the consensus estimate of $6.40 billion. During the same period last year, the firm posted $2.75 EPS. The firm’s revenue for the quarter was down 13.2% on a year-over-year basis. equities research analysts anticipate that Gilead Sciences, Inc. will post 8.53 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be paid a dividend of $0.52 per share. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.87%. Gilead Sciences’s dividend payout ratio is currently 23.69%.

In other Gilead Sciences news, EVP Gregg H. Alton sold 50,000 shares of the firm’s stock in a transaction dated Wednesday, August 30th. The shares were sold at an average price of $79.00, for a total transaction of $3,950,000.00. Following the sale, the executive vice president now directly owns 113,237 shares of the company’s stock, valued at approximately $8,945,723. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Robin L. Washington sold 51,820 shares of the firm’s stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the sale, the chief financial officer now directly owns 43,352 shares in the company, valued at $3,684,920. The disclosure for this sale can be found here. Insiders have sold a total of 666,819 shares of company stock worth $52,303,086 over the last ninety days. 1.30% of the stock is owned by corporate insiders.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.